Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials

Key Points

• The research aims to define metabolic subtypes of nasopharyngeal carcinoma (NPC) that can predict benefits from immunotherapy.
• Defined metabolic subtypes based on biomarker analysis.
• Analyzed data from the Phase III CONTINUUM and DIPPER trials.
• Investigated the association between metabolic subtypes and event-free survival (EFS) from immunotherapy.
• Identified distinct metabolic subtypes of NPC.
• Demonstrated that these subtypes predict EFS benefits from immunotherapy.
• Proposed a novel classification as a predictive biomarker for treatment decision-making.